Insmed discovers, develops, and seeks to commercialize novel, targeted therapies to treat serious rare diseases. The company has received FDA approval for ARIKAYCE (formerly referred to as ALIS) for the treatment of refractory nontuberculous mycobacterial lung infection (NTM) caused by Mycobacterium Avium Complex (MAC) bacteria, and continues to develop ARIKAYCE for front line and maintenance treatment for other non-MAC species. ARIKAYCE is an inhaled liposomal form of FDA-approved amikacin. In addition to ARIKAYCE, INSM is also developing INS1007 for the treatment of Non-Cystic Fibrosis bronchiestasis and INS1009 for the treatment of pulmonary arterial hypertension.

NTM lung disease is associated with increased rates of morbidity and mortality, and MAC is the predominant pathogenic species in NTM lung disease in the United States, Japan, and Europe. The prevalence of NTM lung disease has increased over the past two decades, and is an emerging public health concern worldwide. Researchers have found that the prevalence of NTM in the US was increasing at approximately 8% per year and that NTM patients on Medicare over the age of 65 were 40% more likely to die over the period of the study than those who did not have the disease.